XBiotech (XBIT) versus REDHILL BIOPHAR/S (RDHL) Head to Head Review - Fairfield Current

REDHILL BIOPHAR/S (NASDAQ:RDHL) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

32.3% of REDHILL BIOPHAR/S shares are held by institutional investors. Comparatively, 4.3% of XBiotech shares are held by institutional investors. 37.0% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares REDHILL BIOPHAR/S and XBiotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
REDHILL BIOPHAR/S	-461.55%	-112.99%	-85.25%
XBiotech	N/A	-41.44%	-39.54%

Volatility & Risk

REDHILL BIOPHAR/S has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.

Valuation & Earnings

This table compares REDHILL BIOPHAR/S and XBiotech’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REDHILL BIOPHAR/S	$4.01 million	30.29	-$45.54 million	($2.60)	-2.20
XBiotech	N/A	N/A	-$33.15 million	N/A	N/A

XBiotech has lower revenue, but higher earnings than REDHILL BIOPHAR/S.

Analyst Recommendations

This is a breakdown of current ratings for REDHILL BIOPHAR/S and XBiotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REDHILL BIOPHAR/S	0	0	3	0	3.00
XBiotech	0	0	0	0	N/A

REDHILL BIOPHAR/S presently has a consensus target price of $26.00, indicating a potential upside of 355.34%. Given REDHILL BIOPHAR/S’s higher probable upside, equities analysts plainly believe REDHILL BIOPHAR/S is more favorable than XBiotech.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

XBiotech Company Profile

XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.

http://bit.ly/2EFYoaO